Literature DB >> 21442312

Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples.

Luiz Henrique de Lima Araújo1, Luciana W Pinto, Luciene F Schluckebier, Joyce L de Moraes, Paulo A Faria, Emanuela Moraes, Carlos G Ferreira, Cinthya Sternberg.   

Abstract

Some proteins, canonically not associated with amyloid diseases, can aggregate into amyloid-like fibrils under special conditions. Our group hypothesized that stressful cancer microenvironment might induce the formation of insoluble deposits of p53 mutant protein. A cohort of 28 non-small cell lung cancer (NSCLC) patients was used to test the aforementioned hypothesis. Tumor specimens were assessed for TP53 mutations using DNA sequencing and for amyloid formation by Congo red staining. TP53 mutations were present in 57% of patients, whereas no amyloid deposits were detected in tissue sections under polarized light microscopy. Mutant p53 proteins are not associated with the appearance of amyloid-like fibrils in NSCLC samples, and DNA sequencing remains the standard method to detect such abnormality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442312     DOI: 10.1007/s12032-011-9915-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  9 in total

Review 1.  Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions.

Authors:  Arthur Horwich
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 2.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

Review 3.  On the structural definition of amyloid fibrils and other polypeptide aggregates.

Authors:  M Fändrich
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

4.  Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.

Authors:  Claudia B Levy; Ana C Stumbo; Ana P D Ano Bom; Elisabeth A Portari; Yraima Cordeiro; Yraima Carneiro; Jerson L Silva; Claudia V De Moura-Gallo
Journal:  Int J Biochem Cell Biol       Date:  2010-11-05       Impact factor: 5.085

Review 5.  Amyloidosis-where are we now and where are we heading?

Authors:  Maria M Picken
Journal:  Arch Pathol Lab Med       Date:  2010-04       Impact factor: 5.534

Review 6.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

7.  Fibrillar aggregates of the tumor suppressor p53 core domain.

Authors:  Daniella Ishimaru; Leonardo R Andrade; Luciano S P Teixeira; Pablo A Quesado; Larissa M Maiolino; Priscila M Lopez; Yraima Cordeiro; Lilian T Costa; Wolfgang M Heckl; Gilberto Weissmüller; Debora Foguel; Jerson L Silva
Journal:  Biochemistry       Date:  2003-08-05       Impact factor: 3.162

8.  A primer of amyloid nomenclature.

Authors:  Per Westermark; Merrill D Benson; Joel N Buxbaum; Alan S Cohen; Blas Frangione; Shu-Ichi Ikeda; Colin L Masters; Giampaolo Merlini; Maria J Saraiva; Jean D Sipe
Journal:  Amyloid       Date:  2007-09       Impact factor: 7.141

Review 9.  New insights into systemic amyloidosis: the importance of diagnosis of specific type.

Authors:  Maria M Picken
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-05       Impact factor: 2.894

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.